Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | May 23, 2022 | May 25, 2022 |
| Avantor, Inc.AVTR · Entity 3546 | Director | May 07, 2026 | May 11, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director · Chief Executive Officer | July 28, 2026 | July 30, 2026 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date May 23, 2022 · Filed May 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 152,103 |
Ending reported balance
After 2022-05-23 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2022-05-23 · Exercise / conversion · Acquired 46,320 · Balance 198,423 Row 2 · 2022-05-23 · Exercise / conversion · Acquired 11,742 · Balance 210,165 Row 3 · 2022-05-23 · Exercise / conversion · Acquired 21,739 · Balance 231,904 Row 4 · 2022-05-23 · Sale · Disposed 68,196 · Balance 163,708 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2022-05-23 · Sale · Disposed 11,605 · Balance 152,103 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.36 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2022-05-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-23 · Exercise / conversion · Disposed 46,320 · Balance 0 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.50 · Expires 2030-02-19 | Direct | 38,188 |
Reported balance
After 2022-05-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-23 · Exercise / conversion · Disposed 11,742 · Balance 38,188 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $105.92 · Expires 2031-02-17 | Direct | 43,478 |
Reported balance
After 2022-05-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-23 · Exercise / conversion · Disposed 21,739 · Balance 43,478 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Avantor, Inc.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,821 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 25,270 · Balance 85,821 F1: Reflects a grant of restricted stock units that vests on May 07, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 07, 2027.
Sarepta Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 756,104 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 756,104 · Balance 756,104 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.74 · Expires 2036-07-28 | Direct | 2,224,342 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 2,224,342 · Balance 2,224,342 F2: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment.
F2: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,031 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 25,112 · Balance 25,112 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 919 · Balance 26,031 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 25,112 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 918.455 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 00:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 2,224,342 | $0.00 Strike: $17.74 | $0.00 |
DisclosureSEC source: 0001193125-26-324445 · ownership.xml · derivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,224,342 Underlying: Common Stock · 2,224,342 shares Expires 2036-07-28 F2 · derivative.exercise_date: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 00:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 756,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-324445 · ownership.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 756,104 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:38 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 25,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-033598 · wk-form4_1778531911.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,821 F1 · kind: Reflects a grant of restricted stock units that vests on May 07, 2027. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:03 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 15,890 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008883 · form4.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,890 Underlying: Common Stock · 15,890 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:03 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionDividend Equivalent Units · Derivative | 918.455 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008883 · form4.xml · derivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 918.455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F3 · derivative.expiration_date: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:03 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionRestricted Stock Units · Derivative | 25,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008883 · form4.xml · derivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. F2 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:03 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 919 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008883 · form4.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:03 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 25,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008883 · form4.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2025 Filed May 13, 2025 22:04 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 25,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-018715 · form4.xml · derivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,112 Underlying: Common Stock · 25,112 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2026. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2026. Read SEC document |
| May 08, 2025 Filed May 12, 2025 21:33 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-25-000145 · wk-form4_1747085579.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,551 F1 · kind: Reflects a grant of restricted stock units that vests on May 08, 2026. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:28 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 8,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-24-000113 · wk-form4_1715632104.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,451 F1 · kind: Reflects a grant of restricted stock units that vests on May 09, 2025. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:47 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 9,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-23-000121 · wf-form4_168418361451845.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,974 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2024. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 21,739 | $105.92 Strike: $105.92 | $2,302,594.88 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · derivative · entry 8 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,478 Underlying: Common Stock · 21,739 shares Expires 2031-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 11,742 | $93.50 Strike: $93.50 | $1,097,877.00 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · derivative · entry 7 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,188 Underlying: Common Stock · 11,742 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 46,320 | $114.36 Strike: $114.36 | $5,297,155.20 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · derivative · entry 6 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,320 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 11,605 | $151.53 | $1,758,505.65 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 68,196 | $150.79 | $10,283,274.84 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,708 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 21,739 | $105.92 | $2,302,594.88 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 11,742 | $93.50 | $1,097,877.00 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 46,320 | $114.36 | $5,297,155.20 |
DisclosureSEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 64,636 | $93.50 Strike: $93.50 | $6,043,466.00 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 14 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,930 Underlying: Common Stock · 64,636 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 35,364 | $79.02 Strike: $79.02 | $2,794,463.28 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 13 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,364 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,100 | $155.27 | $326,067.00 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 10 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.27. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 54,279 | $154.49 | $8,385,562.71 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 9 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,203 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.02 to $155.00 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 43,621 | $153.43 | $6,692,770.03 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 8 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,482 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.95 to $153.92 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 64,636 | $93.50 | $6,043,466.00 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 7 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 35,364 | $79.02 | $2,794,463.28 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 6 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 29,121 | $79.20 Strike: $79.02 | $2,306,383.20 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 12 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,364 Underlying: Common Stock · 29,121 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 70,879 | $61.36 Strike: $61.36 | $4,349,135.44 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 11 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,879 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 400 | $155.44 | $62,176.00 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.44. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 53,327 | $154.80 | $8,255,019.60 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,503 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.38 to $154.81 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 46,273 | $154.04 | $7,127,892.92 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,830 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.38 to $154.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 29,121 | $79.02 | $2,301,141.42 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 70,879 | $61.36 | $4,349,135.44 |
DisclosureSEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:17 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 6,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000131 · wf-form4_165273941969121.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,166 F1 · kind: Reflects a grant of restricted stock units that vests on May 12, 2023. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 29,221 | $61.36 Strike: $61.36 | $1,793,000.56 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 21 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,879 Underlying: Common Stock · 29,221 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 70,779 | $58.88 Strike: $58.88 | $4,167,467.52 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 20 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,779 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 48,591 | $152.83 | $7,426,162.53 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 15 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 F9 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 28,536 | $152.24 | $4,344,320.64 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 14 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,694 F8 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 22,873 | $151.16 | $3,457,482.68 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 13 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,230 F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 29,221 | $61.36 | $1,793,000.56 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 12 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 70,779 | $58.88 | $4,167,467.52 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 11 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 33,701 | $58.88 Strike: $58.88 | $1,984,314.88 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 19 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,779 Underlying: Common Stock · 33,701 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 66,299 | $54.86 Strike: $54.86 | $3,637,163.14 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 18 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,299 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 21,071 | $151.42 | $3,190,570.82 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 10 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 31,714 | $150.63 | $4,777,079.82 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 9 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,174 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 47,215 | $149.53 | $7,060,058.95 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 8 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,888 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 33,701 | $58.88 | $1,984,314.88 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 7 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 66,299 | $54.86 | $3,637,163.14 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 6 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 25,691 | $54.86 Strike: $54.86 | $1,409,408.26 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 17 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,299 Underlying: Common Stock · 25,691 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.